Peking Union Medical College Hospital
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Standardized uptake value of 68Ga-FAPI in ACC
Study Overview
Brief Summary
This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）
Detailed Description
68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a rare epithelial malignant tumor, which usually originates from salivary glands. Its typical characteristics are long clinical course and high rate of distant metastasis. The purpose of this study was to investigate the clinical value of 68Ga Fapi pet/ct in metastatic adenoid cystic carcinoma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •patients with ACC suspected metastatic tumor,and being able to provide basic information and sign the written informed consent form
Exclusion Criteria
- •claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study
Arms & Interventions
68Ga-FAPI PET/CT
Imaging was performed 30-60 minutes after injection of 2-4mci 68Ga-FAPI tracer
Intervention: 68Ga-FAPI (Drug)
Outcomes
Primary Outcomes
Standardized uptake value of 68Ga-FAPI in ACC
Time Frame: 1 year
The maximum and mean standard uptake values (SUVmax and SUVmean) were measured in the background of lesion, liver, muscle and mediastinal blood pool, respectively.
Secondary Outcomes
- lesions detected by 68Ga-FAPI PET/CT(1 year)